At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 750 enrolled
Drug / intervention
duloxetine +4 moredrug
Likely dose
duloxetine 120 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode
In Brief
A Phase 4 clinical trial evaluating duloxetine, fluoxetine, and 3 other interventions for Depression. Completed, enrolled 750 participants across 61 sites.
Detailed Summary
The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsBoehringer Ingelheim
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionFeb 2009
Study CompletionMar 2009
TodayJul 2026
First PostedApr 25, 2008
Enrollment StartMay 1, 2008
Primary CompletionFeb 1, 2009
Study CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.2 years ago
Interventions
duloxetinedrug
30-120 milligrams (mgs) orally daily for 12 weeks
fluoxetinedrug
20-80 mgs orally daily for 12 weeks
citalopramdrug
20-40 mgs orally daily for 12 weeks
paroxetinedrug
20-50 mgs orally daily for 12 weeks
sertralinedrug
50-200 mgs orally daily for 12 weeks